Epithalon, a synthetic tetrapeptide consisting of the sequence alanine-glutamate-aspartate-glycine, was developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, where it has been studied since the 1980s. Khavinson's group has produced the majority of the published research on epithalon, which is extensive by peptide standards: dozens of animal studies and several human clinical trials examining its effects on telomere length, pineal gland function, antioxidant activity, and longevity biomarkers. Epithalon is derived from epithalamin, a polypeptide extract from the pineal gland, and it appears to work partly by restoring pineal function that declines with age.
Telomerase Activation
The most widely cited property of epithalon is its activation of telomerase, the enzyme responsible for maintaining telomere length. Telomeres, the protective caps on chromosomes, shorten with each cell division and this shortening is a primary mechanism of cellular senescence and ageing. Telomerase adds telomeric sequence back to chromosomes, maintaining or extending telomere length. In cell culture studies, epithalon has been shown to activate telomerase and extend cell lifespan beyond the Hayflick limit. In animal studies, epithalon-treated animals showed longer telomeres and extended median and maximum lifespans. In human studies, Khavinson's group found measurable increases in telomerase activity in lymphocytes of elderly patients following epithalon treatment.
Pineal Function and Melatonin
The pineal gland, which produces melatonin and regulates circadian rhythms, undergoes progressive calcification and functional decline with age. This decline contributes to circadian rhythm disruption, sleep deterioration, and reduced antioxidant activity, as melatonin is a potent antioxidant as well as a circadian regulator. Epithalon appears to restore pineal function in aged animals, increasing melatonin production and normalising circadian rhythm disruption. The clinical significance of this effect for human ageing is substantial: sleep quality improvements, circadian rhythm normalisation, and enhanced melatonin-mediated antioxidant protection are all relevant to the major health trajectories of ageing.
Anti-Cancer and Immune Effects
Khavinson's group has published extensively on reduced tumour incidence and delayed tumour development in epithalon-treated animals compared to controls. The mechanisms proposed include enhancement of NK cell activity, improved immunosurveillance, and telomere-mediated reduction in genomic instability. Human studies have examined epithalon's effects on markers of immune ageing in elderly patients and found improvements in lymphocyte populations and functional immune markers. These are encouraging findings, but the quality and independence of the evidence base, with the majority of research coming from a single research group, means that results should be interpreted with appropriate caution pending independent replication.
Protocols and Considerations
Epithalon is typically administered by subcutaneous injection at doses of 5 to 10mg per day for courses of 10 to 20 days, repeated annually or biannually in human clinical protocols. Oral bioavailability is likely poor due to peptide degradation in the gastrointestinal tract, making injectable administration the most common approach in clinical research. Intranasal formulations have been explored. Epithalon appears to have a favourable safety profile in both animal and human studies, with no significant adverse effects reported in the available literature. However, as with all peptides used outside a licensed pharmaceutical context, quality and purity of the source compound are critical safety considerations.